Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 14 unusual trades.
金融巨头对再生元制药公司做出了明显的看淡动作。我们对再生元制药公司（NASDAQ: REGN）期权历史的分析表明，共有14宗不寻常的交易。
Delving into the details, we found 14% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $721,270, and 10 were calls, valued at $1,045,138.
详细了解后发现，14%的交易者看好该股，而50%则表现出看淡的倾向。我们发现，所有交易中有4单看跌期权，价值721,270美元，有10单看涨期权，价值1,045,138美元。
Projected Price Targets
预计价格目标
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $960.0 to $1280.0 for Regeneron Pharmaceuticals over the last 3 months.
考虑到这些合同的成交量和持仓量，近3个月来庞大的交易者似乎一直瞄准再生元制药公司的价格区间在$960.0到$1280.0之间。
Analyzing Volume & Open Interest
分析成交量和未平仓合约
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Regeneron Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Regeneron Pharmaceuticals's significant trades, within a strike price range of $960.0 to $1280.0, over the past month.
检查成交量和持仓量可以提供关于股票研究的重要见解。这些信息对于评估再生元制药公司在特定行权价格的期权的流动性和利益水平至关重要。下面，我们介绍过去一个月内再生元制药公司重要交易的看跌和看涨期权的成交量和持仓量趋势。这些期权在行权价格范围为$960.0至$1280.0之间。
Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
再生元制药公司过去30天的期权成交量和持仓量
Significant Options Trades Detected:
检测到重大期权交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | CALL | TRADE | NEUTRAL | 01/17/25 | $160.3 | $152.0 | $156.6 | $980.00 | $454.1K | 200 | 0 |
| REGN | PUT | TRADE | BEARISH | 06/20/25 | $99.0 | $91.5 | $96.0 | $1100.00 | $384.0K | 3 | 0 |
| REGN | PUT | TRADE | NEUTRAL | 12/18/26 | $112.0 | $102.0 | $107.0 | $1040.00 | $214.0K | 0 | 0 |
| REGN | CALL | TRADE | BEARISH | 06/20/25 | $58.0 | $55.0 | $55.0 | $1280.00 | $165.0K | 19 | 0 |
| REGN | PUT | TRADE | BEARISH | 01/17/25 | $33.5 | $27.3 | $31.3 | $980.00 | $90.7K | 117 | 0 |
| 标的 | 看跌/看涨 | 交易类型 | 情绪 | 到期日 | 卖盘 | 买盘 | 价格 | 执行价格 | 总交易价格 | 未平仓合约数量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 再生元制药公司 | 看涨 | 交易 | 中立 | 01/17/25 | $160.3 | 152.0美元 | $156.6 | 980.00美元。 | $454.1K | 200 | 0 |
| 再生元制药公司 | 看跌 | 交易 | 看淡 | 06/20/25 | $99.0 | $91.5 | $96.0 | $1100.00 | $384.0K | 3 | 0 |
| 再生元制药公司 | 看跌 | 交易 | 中立 | 12/18/26 | $112.0 | $102.0 | $107.0 | $1040.00 | $214.0K | 0 | 0 |
| 再生元制药公司 | 看涨 | 交易 | 看淡 | 06/20/25 | $58.0 | $55.0 | $55.0 | $1280.00 | $165.0K | 19 | 0 |
| 再生元制药公司 | 看跌 | 交易 | 看淡 | 01/17/25 | $33.5 | $27.3 | $31.3 | 980.00美元。 | $90.7K | 117 | 0 |
About Regeneron Pharmaceuticals
关于再生元制药公司
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
再生元制药公司发现、开发和商业化对抗眼部疾病、心血管疾病、癌症和炎症的药物。该公司拥有几种上市产品，包括用于湿性年龄相关性黄斑变性和其他眼病的艾立雅；用于降低低密度脂蛋白胆固醇的普遍；在免疫学上的杜派珊；在肿瘤学上的力比多；以及在类风湿性关节炎上的科瓦匝。再生元制药公司还与赛诺菲安万特、其他合作伙伴和独立开发单克隆和双特异性抗体，并有较早阶段的合作伙伴关系，为管道带来新的技术，包括RNAi（Alnylam）和CRISPR基因编辑（Intellia）。
Following our analysis of the options activities associated with Regeneron Pharmaceuticals, we pivot to a closer look at the company's own performance.
在分析再生元制药公司的期权活动后，我们转而更近距离地审视公司本身的表现。
Where Is Regeneron Pharmaceuticals Standing Right Now?
再生元制药公司目前处于什么位置？
- With a trading volume of 322,187, the price of REGN is down by 0.0%, reaching $1063.89.
- Current RSI values indicate that the stock is may be overbought.
- Next earnings report is scheduled for 37 days from now.
- 交易量为322,187，REGN的价格下跌了0.0%，达到了1063.89美元。
- 当前RSI值表明股票可能已经超买。
- 下一个盈利报告将在 37 天后发布。
What The Experts Say On Regeneron Pharmaceuticals
专家对再生元制药公司的看法如何？
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1195.6.
过去30天内，共有5名专业分析师对此股票发表了看法，设定平均目标价格为$1195.6。
- An analyst from JP Morgan has decided to maintain their Overweight rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1150.
- Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Regeneron Pharmaceuticals, targeting a price of $1200.
- An analyst from RBC Capital downgraded its action to Outperform with a price target of $1229.
- An analyst from Argus Research persists with their Buy rating on Regeneron Pharmaceuticals, maintaining a target price of $1170.
- Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1229.
- JP摩根的一名分析师决定维持对再生元制药公司的超配评级，目前股价目标为1150美元。
- RBC Capital的一名分析师继续保持看好再生元制药公司的立场，目标价格为1200美元。
- 来自RBC Capital的一位分析师下调其评级，将目标价设定为1229美元人民币。
- 雅运股份的一位分析师对再生元制药公司的买入评级持续，并保持1170美元人民币的目标价。
- RBC Capital的一位分析师在评估中一贯性地保持其买入评级的同时设置了1229美元人民币的目标价。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
期权交易存在更高的风险和潜在的回报。精明的交易者通过不断教育自己，调整策略，监测多种因子，并密切关注市场动向来管理这些风险。通过Benzinga Pro实时提醒了解关于最新的再生元制药公司期权交易的信息。